Indian biopharmaceutical company Biocon Limited (NSE:BIOCON) is seeking a partner to test generic versions of Novo Nordisk's (CPH:NOVO-B) diabetes drug Ozempic and weight loss treatment Wegovy in China, Reuters reported on Thursday.
An unnamed senior executive told the news agency that Biocon is looking for a Chinese partner for clinical trials on patients in order to sell the drug in China.
Biocon is aiming to launch generic versions of the drugs globally.
Patent protection on semaglutide, a key ingredient in both Ozempic and Wegovy, is due to expire in China in early 2026.
Hikma Pharmaceuticals extends KLOXXADO nasal spray shelf-life 8mg from 24 to 36 months
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
Emmaus Life Sciences names new chief executive officer
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)